Ansarullah,
Jain, Chirag
Far, Fataneh Fathi
Homberg, Sarah
Wißmiller, Katharina http://orcid.org/0000-0002-0224-7563
von Hahn, Felizitas Gräfin
Raducanu, Aurelia
Schirge, Silvia
Sterr, Michael
Bilekova, Sara http://orcid.org/0000-0001-6699-1386
Siehler, Johanna
Wiener, Julius
Oppenländer, Lena
Morshedi, Amir
Bastidas-Ponce, Aimée
Collden, Gustav
Irmler, Martin http://orcid.org/0000-0003-3169-479X
Beckers, Johannes
Feuchtinger, Annette
Grzybek, Michal
Ahlbrecht, Christin
Feederle, Regina http://orcid.org/0000-0002-3981-367X
Plettenburg, Oliver
Müller, Timo D. http://orcid.org/0000-0002-0624-9339
Meier, Matthias
Tschöp, Matthias H. http://orcid.org/0000-0002-4744-371X
Coskun, Ünal http://orcid.org/0000-0003-4375-3144
Lickert, Heiko http://orcid.org/0000-0002-4597-8825
Article History
Received: 24 February 2020
Accepted: 14 December 2020
First Online: 27 January 2021
Change Date: 12 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-021-03347-z
Competing interests
: The Helmholtz Center Munich GmbH has filed a patent application “Novel IGFR-like receptor and uses thereof” (inventor: H.L.), which is pending (WO2017042242), covering the targeting of inceptor for diabetes therapy. Another Helmholtz Center Munich GmbH priority application is under preparation. No application number is yet available, but the title of the patent application will be “Novel IGFR-like 1 monoclonal antibodies and uses thereof”, covering the targeting of inceptor for various medical applications (inventors will be H.L., Ü.C. and M.G.).